Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit
Sidiropoulos, P, Bertsias, G, Kritikos, H D, Kouroumali, H, Voudouris, K, Boumpas, D T
Published in Annals of the rheumatic diseases (01.02.2004)
Published in Annals of the rheumatic diseases (01.02.2004)
Get full text
Journal Article
An open label, single dose study to evaluate the safety, efficacy, and effects on CD25 expression of ciclosporin in patients with active rheumatoid arthritis despite treatment with methotrexate and infliximab
Sidiropoulos, P I, Siakka, P, Raptopoulou, A, Mamoulaki, M, Choulaki, C, Koutala, H, Kouroumali, H, Kritikos, H, Boumpas, D T
Published in Annals of the rheumatic diseases (01.04.2006)
Published in Annals of the rheumatic diseases (01.04.2006)
Get full text
Journal Article
Low dose of infliximab is inadequate in most patients with spondylarthropathies
SIDIROPOULOS, P, KRITIKOS, H. D, SIAKKA, P, MAMOULAKI, M, KOUROUMALI, H, VOUDOURIS, K, BOUMPAS, D. T
Published in Clinical and experimental rheumatology (01.07.2005)
Get full text
Published in Clinical and experimental rheumatology (01.07.2005)
Journal Article
Addition of cyclosporine-A (Neoral®) in patients on anti-TNF and methotrexate therapy improves disease activity: an open-label, pilot study
Sidiropoulos, P, Siakka, P, Mamoulaki, M, Kouroumali, H, Kritikos, H, Boumpas, DT
Published in Arthritis research & therapy (2004)
Published in Arthritis research & therapy (2004)
Get full text
Journal Article